{"id":"tyrosine-kinase-inhibitor","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Rash"},{"rate":"10-30%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tyrosine kinases are enzymes responsible for the activation of proteins by signal transduction cascades. By inhibiting these enzymes, tyrosine kinase inhibitors can prevent the growth and spread of cancer cells. This class of drugs is often used in the treatment of various types of cancer.","oneSentence":"Tyrosine kinase inhibitors block the activity of specific enzymes called tyrosine kinases, which are involved in the activation of proteins by signal transduction cascades.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:53.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Chronic myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT07498595","phase":"EARLY_PHASE1","title":"TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-03-31","conditions":"EGFR-TKI-resistant Non-Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT05768932","phase":"PHASE1","title":"BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"SillaJen, Inc.","startDate":"2022-12-14","conditions":"Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer","enrollment":260},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT01841723","phase":"PHASE2","title":"Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-04-30","conditions":"Hairy Cell Leukemia, Hairy Cell Leukemia Variant, Recurrent Hairy Cell Leukemia","enrollment":44},{"nctId":"NCT05131022","phase":"PHASE1","title":"A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2022-04-13","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":572},{"nctId":"NCT07495579","phase":"PHASE2","title":"Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-04","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":146},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT02503722","phase":"PHASE1","title":"Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-23","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7","enrollment":36},{"nctId":"NCT02496663","phase":"PHASE1","title":"Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-11","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":138},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT05068440","phase":"PHASE2","title":"Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-08-11","conditions":"Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma","enrollment":65},{"nctId":"NCT07493408","phase":"PHASE2","title":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-30","conditions":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)","enrollment":45},{"nctId":"NCT05388006","phase":"PHASE2","title":"Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-01-05","conditions":"Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma","enrollment":27},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT07171203","phase":"PHASE1","title":"Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-06","conditions":"Gastrointestinal Stromal Tumors","enrollment":18},{"nctId":"NCT02650401","phase":"PHASE1, PHASE2","title":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2016-05-03","conditions":"Solid Tumors, CNS Tumors","enrollment":69},{"nctId":"NCT04107727","phase":"PHASE2","title":"Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-09-05","conditions":"Acute Myeloid Leukemia","enrollment":273},{"nctId":"NCT05805631","phase":"PHASE2","title":"Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC","status":"RECRUITING","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2024-08-01","conditions":"Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis","enrollment":23},{"nctId":"NCT06588478","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2025-01-03","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":249},{"nctId":"NCT02446236","phase":"PHASE1","title":"Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2015-06-18","conditions":"Mantle Cell Lymphoma","enrollment":27},{"nctId":"NCT06863402","phase":"PHASE2","title":"Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-15","conditions":"Richter Syndrome, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia","enrollment":32},{"nctId":"NCT07185997","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","status":"RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2025-12-17","conditions":"Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer","enrollment":480},{"nctId":"NCT07489755","phase":"PHASE3","title":"TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2026-04-01","conditions":"Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":180},{"nctId":"NCT07354074","phase":"PHASE2","title":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-04","conditions":"Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive","enrollment":50},{"nctId":"NCT05143840","phase":"PHASE2","title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"Augusta University","startDate":"2022-04-22","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid","enrollment":100},{"nctId":"NCT04115631","phase":"PHASE2","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-12-13","conditions":"Liver Lymphoma, Mantle Cell Lymphoma","enrollment":360},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT01479842","phase":"PHASE1","title":"Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kami Maddocks, MD","startDate":"2014-03-26","conditions":"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma","enrollment":48},{"nctId":"NCT06211413","phase":"","title":"Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors","status":"ENROLLING_BY_INVITATION","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2024-02-07","conditions":"Chronic Lymphocytic Leukemia, Atrial Fibrillation, Hypertension","enrollment":50},{"nctId":"NCT02180724","phase":"PHASE2","title":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2014-09-11","conditions":"Waldenström Macroglobulinemia (WM)","enrollment":107},{"nctId":"NCT04830137","phase":"PHASE1","title":"A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2021-05-05","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM)","enrollment":248},{"nctId":"NCT06360575","phase":"PHASE2","title":"Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-20","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":20},{"nctId":"NCT06705686","phase":"PHASE1","title":"Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"TechnoGenesys, Inc.","startDate":"2026-03-13","conditions":"Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma","enrollment":40},{"nctId":"NCT05748834","phase":"PHASE2","title":"Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-07-24","conditions":"Breast Cancer","enrollment":36},{"nctId":"NCT07049926","phase":"PHASE1, PHASE2","title":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-20","conditions":"Renal Cell Carcinoma","enrollment":140},{"nctId":"NCT03737994","phase":"PHASE2","title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-25","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":10},{"nctId":"NCT07100080","phase":"PHASE2, PHASE3","title":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-11-05","conditions":"Non-Small Cell Lung Cancer","enrollment":596},{"nctId":"NCT02365597","phase":"PHASE2","title":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2015-04-22","conditions":"Urothelial Cancer","enrollment":239},{"nctId":"NCT06357975","phase":"PHASE2","title":"Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-29","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":44},{"nctId":"NCT06671379","phase":"PHASE3","title":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-11-29","conditions":"Non-small Cell Lung Cancer","enrollment":498},{"nctId":"NCT07479732","phase":"PHASE1, PHASE2","title":"Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-03-05","conditions":"Osteosarcoma, Osteosarcoma Metastatic","enrollment":56},{"nctId":"NCT06552234","phase":"PHASE2","title":"Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC","status":"RECRUITING","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2024-10-01","conditions":"NSCLC Stage IV, NSCLC, Stage III","enrollment":30},{"nctId":"NCT04948333","phase":"PHASE3","title":"Asciminib Treatment Optimization in ≥ 3rd Line CML-CP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-13","conditions":"Chronic Myelogenous Leukemia","enrollment":199},{"nctId":"NCT07277231","phase":"PHASE3","title":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2026-01-22","conditions":"Chronic Lymphocytic Leukemia","enrollment":500},{"nctId":"NCT06973187","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-09-04","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":500},{"nctId":"NCT07122882","phase":"","title":"Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance","status":"ENROLLING_BY_INVITATION","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-09-01","conditions":"Oncogene-addicted Non Small Cell Lung Cancer, EGFR Mutation, ALK Fusion-positive Solid or CNS Tumors","enrollment":40},{"nctId":"NCT02947347","phase":"PHASE3","title":"Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-01-23","conditions":"Follicular Lymphoma","enrollment":445},{"nctId":"NCT07221500","phase":"PHASE2","title":"A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2025-10-15","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)","enrollment":100},{"nctId":"NCT07235085","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy","status":"RECRUITING","sponsor":"Ocular Therapeutix, Inc.","startDate":"2025-11-17","conditions":"Non-Proliferative Diabetic Retinopathy","enrollment":930},{"nctId":"NCT07449936","phase":"PHASE3","title":"COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-26","conditions":"Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)","enrollment":240},{"nctId":"NCT01248429","phase":"","title":"Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2010-11","conditions":"Cancer, Solid Tumor","enrollment":154},{"nctId":"NCT04693468","phase":"PHASE1","title":"Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-01","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":111},{"nctId":"NCT06572618","phase":"PHASE2","title":"Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-01-22","conditions":"Mantle Cell Lymphoma","enrollment":27},{"nctId":"NCT07469683","phase":"PHASE2","title":"An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2026-03","conditions":"Clear Cell Renal Cell Carcinoma, Neoplasms, Malignant Neoplasms","enrollment":78},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT07459608","phase":"PHASE2","title":"Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-03-10","conditions":"Indolent Lymphoma, WM, MZL","enrollment":75},{"nctId":"NCT02203526","phase":"PHASE1","title":"Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-08-14","conditions":"Primary Central Nervous System Lymphoma","enrollment":93},{"nctId":"NCT05364073","phase":"PHASE1","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2022-06-30","conditions":"Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer","enrollment":160},{"nctId":"NCT01804686","phase":"PHASE3","title":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-09","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma","enrollment":700},{"nctId":"NCT06799000","phase":"PHASE3","title":"A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-01-31","conditions":"Hidradenitis Suppurativa","enrollment":555},{"nctId":"NCT07193316","phase":"","title":"Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-07-27","conditions":"Hepatocellular Carcinoma, Liver Cirrhosis","enrollment":38},{"nctId":"NCT07467590","phase":"PHASE2","title":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-01","conditions":"Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response","enrollment":33},{"nctId":"NCT05513001","phase":"PHASE3","title":"An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-12-09","conditions":"Chronic Spontaneous Urticaria","enrollment":696},{"nctId":"NCT06775743","phase":"PHASE2","title":"ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-01-15","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer","enrollment":53},{"nctId":"NCT07039760","phase":"EARLY_PHASE1","title":"Asciminib With or Without Sildenafil for Brain Tumors","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-04-30","conditions":"Brain Tumor","enrollment":12},{"nctId":"NCT06840392","phase":"PHASE3","title":"A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-03-20","conditions":"Hidradenitis Suppurativa","enrollment":555},{"nctId":"NCT06282991","phase":"","title":"A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-07-22","conditions":"Non-Small Cell Lung Carcinoma","enrollment":73},{"nctId":"NCT05256641","phase":"PHASE1, PHASE2","title":"Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2023-01-23","conditions":"Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma","enrollment":24},{"nctId":"NCT05824481","phase":"PHASE2","title":"Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-08","conditions":"Endometrial Cancer, Endometrial Adenocarcinoma","enrollment":32},{"nctId":"NCT06229860","phase":"","title":"Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2024-01-25","conditions":"Chronic Myeloid Leukemia, Chronic Phase Chronic Myelogenous Leukemia","enrollment":75},{"nctId":"NCT05824468","phase":"PHASE2","title":"Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-10","conditions":"Cervical Cancer, Cervical Carcinoma","enrollment":30},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT05494580","phase":"PHASE1, PHASE2","title":"Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2022-09-22","conditions":"Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer","enrollment":29},{"nctId":"NCT05636267","phase":"PHASE1, PHASE2","title":"Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients","status":"TERMINATED","sponsor":"Akeso","startDate":"2023-02-10","conditions":"NSCLC","enrollment":59},{"nctId":"NCT04222972","phase":"PHASE3","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-24","conditions":"RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung","enrollment":223},{"nctId":"NCT06114940","phase":"PHASE2","title":"Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)","status":"TERMINATED","sponsor":"Jinling Hospital, China","startDate":"2022-12-20","conditions":"Renal Cell Carcinoma (RCC)","enrollment":17},{"nctId":"NCT07449923","phase":"PHASE3","title":"CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-09","conditions":"Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)","enrollment":240},{"nctId":"NCT06813664","phase":"PHASE2","title":"ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-04-01","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer, OligoProgressive Metastatic Disease","enrollment":60},{"nctId":"NCT06760819","phase":"PHASE2","title":"A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-02-13","conditions":"Advanced Solid Tumors, HER2 Mutation","enrollment":111},{"nctId":"NCT05640102","phase":"","title":"Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia","status":"RECRUITING","sponsor":"BeiGene","startDate":"2023-03-03","conditions":"Waldenstrom Macroglobulinemia","enrollment":111},{"nctId":"NCT05184712","phase":"PHASE3","title":"Phase 3 Clinical Study of AK112 for NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-01-25","conditions":"Non-Squamous Non-small Cell Lung Cancer","enrollment":322},{"nctId":"NCT07449065","phase":"","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI)","enrollment":324},{"nctId":"NCT06668064","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-10-22","conditions":"Wet Age Related Macular Degeneration, wAMD","enrollment":400},{"nctId":"NCT06683742","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-11-27","conditions":"Wet Age Related Macular Degeneration, wAMD","enrollment":400},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT03516279","phase":"PHASE2","title":"Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-06-26","conditions":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease","enrollment":40},{"nctId":"NCT03514017","phase":"PHASE2","title":"Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-05-31","conditions":"Chronic Lymphocytic Leukemia","enrollment":5},{"nctId":"NCT04216563","phase":"PHASE2","title":"ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-29","conditions":"Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia","enrollment":7},{"nctId":"NCT04318938","phase":"PHASE2","title":"Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2020-03-30","conditions":"NSCLC","enrollment":118},{"nctId":"NCT06151730","phase":"","title":"Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-05","conditions":"Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma","enrollment":100},{"nctId":"NCT02716116","phase":"PHASE1, PHASE2","title":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2016-06-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":334},{"nctId":"NCT06524375","phase":"PHASE2","title":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2024-08-09","conditions":"Chronic Lymphocytic Leukemia","enrollment":118},{"nctId":"NCT06521554","phase":"PHASE1","title":"A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)","status":"RECRUITING","sponsor":"Nuvalent Inc.","startDate":"2024-07-18","conditions":"Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":200},{"nctId":"NCT04169737","phase":"PHASE2","title":"Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-29","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":168},{"nctId":"NCT05438420","phase":"PHASE1, PHASE2","title":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qurient Co., Ltd.","startDate":"2023-01-12","conditions":"Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer","enrollment":120},{"nctId":"NCT05990465","phase":"PHASE1","title":"LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-02-06","conditions":"Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma","enrollment":12},{"nctId":"NCT06016387","phase":"PHASE2","title":"Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-11-25","conditions":"HER2-positive Breast Cancer, LMD","enrollment":30},{"nctId":"NCT04868877","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merus B.V.","startDate":"2021-04-28","conditions":"Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma","enrollment":194},{"nctId":"NCT07419932","phase":"","title":"Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer","status":"RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-12-23","conditions":"Thyroid Cancer, Thyroid Neoplasms","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24247,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Study treatment","Protein Tyrosine Kinase Inhibitors","PTK Inhibitors","TK Inhibitors","TKI"],"phase":"phase_3","status":"active","brandName":"Tyrosine kinase inhibitor","genericName":"Tyrosine kinase inhibitor","companyName":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","companyId":"institut-f-r-klinische-krebsforschung-ikf-gmbh-at-krankenhaus-nordwest","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tyrosine kinase inhibitors block the activity of specific enzymes called tyrosine kinases, which are involved in the activation of proteins by signal transduction cascades. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Chronic myeloid leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}